Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06748001 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Avapritinib Rollover Study

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 6 to 7v6
  2. Study sites: 5 to 6v5
  3. Study sites: 4 to 5v4
  4. Study sites: 3 to 4v3
  5. Study sites: 1 to 3v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Trial Details
NCT Number NCT06748001
Lead Sponsor Blueprint Medicines Corporation
Conditions
(from sponsor)		 Mastocytosis, Systemic
Related terms Mastocytosis, Systemic
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov